Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Srinivas Rao | M | 55 |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | 5 years |
Jonathan Sporn | M | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
Dalibor Sames | M | - |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY.
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
Jeff Witkin | M | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
Mike Cunningham | M | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
Errol de Souza | M | 70 |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | - |
Dakin Sloss | M | 33 |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | 2 years |
Chad E. Beyer | M | - |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | 2 years |
Phil Skolnick | M | 77 |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
Nicholas Haft | M | - |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | - |
Kevin T. Murphy | M | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
Amy Kruse | F | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
Robert Berman | M | - |
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gilgamesh Pharmaceuticals, Inc. engages in the development of drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Its products pipeline include Arylcyclohexylamine, Serotonergic Micro-Dose, and Novel Ibogaine Analogue. The company was founded by Jonathan Sporn, Dalibor Sames, Andrew Kruegel, Jeff Witkin, and Mike Cunningham and is headquartered in New York, NY. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 13 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew Carry Kruegel
- Personal Network